Gedea Biotech

Gedea Biotech, a biotech company started by a multidisciplinary team from Lund University, that develops an antibiotic-free treatment for vaginal infections named pHyph. pHyph can be used to treat vaginal thrush and bacterial vaginosis. Vaginal infections, such as vaginal thrush and bacterial vaginosis, are caused by fungi and bacteria growing under a biofilm and furthermore alter the natural pH of the vagina. pHyph can be used to break down this biofilm, which causes the fungi to turn into a harmless yeast form and restores the pH to its natural level. The yeast will then be secreted and with the return to normal pH levels, the bacterial flora will revert to its normal state.

Gedea Biotech has verified the effectiveness of the treatment in in-vitro studies as well as the safety and stability of the treatment. Two clinical studies are currently conducted to show the effectiveness of both bacterial vaginosis and fungal infections.

“As a result of being part of NOME, we got a very valuable sounding board that is separate from the board of Gedea and the owners, the mentors gave an outside-in perspective, and a valuable network nationally and internationally. Since the mentors are involved for 2 years, they get an understanding of the conditions in which we work. This means that they can give real advice and not trivial advice that other coaches give after a day of workshops.”

CEO Annette Säfholm leads a strong team with business and research experience from academia, life science start-ups and big pharma. Gedea Biotech is based in Lund, Sweden, joined NOME in 2018, and graduated in 2021.